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UMBILICAL CORD BLOOD TRANSPLANTATION FOR TRANSFUSION-
DEPENDENT THALASSEMIA AND SICKLE CELL DISEASE
Walters, Mark. Children’s Hospital Oakland Research Institute, Oak-
land, CA.
Sickle cell anemia and -thalassemia major are clinically signiﬁ-
cant hereditary anemias that elicit world-wide attention due to the
frequency and severity of these disorders. Historically, most chil-
dren who inherited these disorders died in the ﬁrst decade of life.
In the contemporary era, however, supportive care has extended
lifespan through the 5th decade of life and beyond, with survival
through early adulthood now indistinguishable from those unaf-
fected by these disorders. As a result, chronic health impairments
that signiﬁcantly reduce the quality of life have become the prin-
cipal challenge in -thalassemia major and sickle cell anemia.
Thus, the application of hematopoietic cell transplantation and its
inherent risk of mortality in the short-term must be balanced by
the beneﬁt of survival without the burden of chronic illness in the
long-term. Toward this end, the development of umbilical cord
blood transplantation (UCBT) represents a signiﬁcant advance due
to its association with a lower risk of graft-versus-host disease
(GVHD), the leading cause of mortality and morbidity after HCT
for hemoglobinopathies. We have observed outcomes after UCBT
that are identical to earlier results of bone marrow transplantation
for hemoglobinopathies. In our multi-center series of patients
treated by HLA-identical sibling UCBT, 26 of 29 (90%) survive,
and 25 (86%) survive disease-free. Overall, the Kaplan-Meier
probabilities of survival and event-free survival after sibling UCBT
are 89% and 86%, respectively with a median follow-up of 1.3
(range, 0.1-7.6) years. The cumulative incidence of graft failure was
4%. Results after unrelated donor UCBT remain limited, but
suggest encouraging results, particularly with regard to the rates of
acute and chronic GVHD. UCBT in lieu of more conventional
sources of hematopoietic cells may be particularly advantageous when
there is urgency for transplantation and in non-malignant disorders
where GVHD, in particular, has a negative impact upon outcome.
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UNRELATED CORD BLOOD TRANSPLANTATION (CBT) FOR HEMOGLO-
BINOPATHY
Jaing, Tang-Her,1 Tan, Patrick,2 Rosenthal, Joseph,3 Wang, Brian,4
Gjertson, David,4,5 Petz, Lawrence D.,5,6 Chow, Robert.6,7,8 1Chang
Gung University & Children’s Hospital, Linko, Taiwan; 2Haematology
& Stem Cell Transplant Center, Mount Elizabeth Hospital, Singapore;
3City of Hope National Medical Center, Duarte, CA; 4UCLA School of
Public Health and 5UCLA Medical Center, Los Angeles, CA; 6StemCyte
International Cord Blood Center, Arcadia, CA; 7StemCyte Taiwan
National Cord Blood Center, Linko, Taiwan; 8StemCyte Research In-
stitute, Arcadia, CA.
Unrelated umbilical cord blood transplantation (CBT) is a po-
tentially curative therapy for most hemoglobinopathy patients;
however, cell dosage is a critical factor for CBT. We previously
showed that by combining strategies that maximize cell dose, that
is, non-red cell reduced plasma depleted cord blood (PD CB),
forego post-thaw wash, and double cord blood transplantation
when needed—promising results may be achieved with unrelated
CBT in selected patients (Jaing et al, BBMT 2005;11:349). Be-
tween July 1991 and April 2006, 45 unrelated CBT were per-
formed after myeloablative therapy in 38 pediatric patients with
transfusion-dependent hemoglobinopathy (36 thalassemia and 2
SCD) at the authors’ institutions and 11 other centers using mostly
PDCB units that were not washed after thawing (6 double cords
and 1 re-transplant). Nineteen patients were Pesaro class 1, four
class 2, and one class 3, with 14 status unknown. The median age
of patients was 6 years old (range 0.3-20 yr) with a median weight
of 19 kg (range 8-76 kg). All PD CB data were audited internally
and externally and the primary data for the 15 patients at Chang
Gung were audited by one of the authors (JR).
No signiﬁcant adverse events were observed after direct infusion
despite major ABO incompatibility in 9 cases.
Unadjusted ANC 500 and platelet 20,000 engraftment cumulative
incidence with donor chimerism was achieved in 81  7% and 79 
8% of the cases, and median times to ANC500 engraftment, and
platelet 20,000 engraftment were 17 (range 11-33 days) and 37 (range
16-133 days) days after transplantation, respectively (Table 4).
Eight patients died with 3 deaths unrelated to the CBU (2 early
deaths prior to day 20 and one accident). All remaining 30 patients
Table 4. Summary of Clinical Outcome Based on Experience and Washing
Autologous
Recovery 1 Yr. OS
1 Yr.
DFS
Unadjusted Cumulative Incidence
III-IV aGVHD
Extensive
cGVHDANC500 Plt20K Plt50K
Less experienced 15% 63% 45% 71% 56% 56% 0% 0%
Experienced 11% 87% 77% 87% 86% 86% 16% 10%
Not Washed 12% 83% 72% 83% 86% 82% 13% 8%
Washed 17% 55% 26% 70% 40% 40% 0% 0%
Overall 13  6% 77  7% 65  8% 81  7% 79  8% 76  8% 11% 6%
Table 5. Summary of Graft Parameters Based on Experience and Washing
Patients,
n
CBU,
n
HLA
Matches, n
Prefreeze
TNC Dose
Post-thaw
TNC Dose
TNC
Recovery
Prefreeze
CD34 Dose
Post-thaw
CD34 Dose
CD34 Cell
Recovery
Less experienced 15 15 5.0 6.8 2.6 83% 3.6 1.1 39%
Experienced 23 30 4.0 8.9 6.6 89% 3.4 3.3 99%
Not washed 31 38 4.0 9.1 5.6 81% 3.5 2.9 83%
Washed 7 7 5.0 6.4 2.1 NA 3.9 3.1 NA
Overall 38 45 4.0 8.1 5.6 82% 3.4 2.9 84%
Table 3. Interaction between HLA Mismatches, Number of Cells and
Outcomes in Unrelated Cord Blood Transplants for Non-Malignant
Diseases
Number of
HLA MM 0-1
vs 2 vs 3-4
Type of
HLA MM
Class I vs II
Interaction with
Number of Cells
PMN engraftment Less More 2 DRB1  Less <cells and >MM
Platelet engraftment Less More 2 DRB1  Less <cells and >MM
TRM More Less 2 DRB1  Less <cells and >MM
AGVHD More Same More >cells and >MM
CGVHD More Same More >cells and >MM
LFS, OS Less Better 2 DRB1  Worse if HLA MM >2 and
NC <3.5 NC/kg
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are alive (5 with autologous recovery) with 25 thalassemia free with
a mean and median follow up time of 392 and 257 days respectively
(range 7-1,760 days) as of April 28, 2006. The median day to
hospital discharge was day 58 (range 22-137 days). An analysis
was undertaken to compare experienced centers (5 cases) with
less experienced centers, as well as compare units that were post-
thaw washed versus units that were not post-thaw washed (Table
5). These results show that when cell dose is optimal and post-thaw
wash is not used, at experienced centers, unrelated CBT may be a
promising approach for the curative therapy of thalassemia major.
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REDUCED INTENSITY CONDITIONING IN STEM CELL TRANSPLANTA-
TION FOR NON-MALIGNANT DISORDERS
Shenoy, Shalini. Washington University School of Medicine and Saint
Louis Children’s Hospital, Saint Louis, MO.
Background: Hematopoietic stem cell transplantation (HSCT)
is curative in several non-malignant disorders including hemoglo-
binopathies. It is limited by donor availability, regimen related
toxicities, graft rejection, and GVHD. HSCT is often restricted to
myeloablative regimen and matched related donors.
Study objective: To determine whether children with non-
malignant disorders achieve donor engraftment with lowered tox-
icity following reduced intensity conditioning (RIT).
Study design: Fifty-two children received related or unrelated
donor transplants after conditioning with Campath-1H, ﬂudara-
bine, and melphalan (140 or 70 mg/m2). GVHD prophylaxis in-
cluded cyclosporine or tacrolimus, short course methotrexate (3
doses), and methyl prednisone. Patients were 8 months to 20 years
old; 4 had failed previous transplants; 12 had received transfusion
therapy for 8 months to 12 years. Indications for HSCT included
hemoglobinopathy (6), bone marrow failure (7), immune dysfunc-
tion (25), metabolic disorders (13) and autoimmunity (1). Marrow/
peripheral blood (41) was 7-8/8 allele matched and cord blood (11)
was 4-5/6 antigen matched.
Results: All but 2 patients, both with hemoglobinopathy who
received the lower melphalan dose, engrafted. Myeloid (ANC0.5
109/L) and platelet (50 109/L) engraftment occurred at a median
of 13 (10-36) and 26 (12-82) days. At median follow up of 14 months
(5-52), overall and event free survival were 87% and 77%. Treatment
related mortality was 11%. Grade 2-4 acute GVHD developed in
15%; chronic GVHD in 11% between 6-9 months post transplant.
Post transplant complications were predominantly bacterial and viral
infections; all in the ﬁrst 6 months post HSCT. Hemoglobinopathy
patients tolerated conditioning without toxicity and successfully en-
grafted donor cells only with the higher dose of melphalan.
Conclusions: This RIT regimen was well tolerated and achieved
donor engraftment irrespective of stem cell source in non-malig-
nant disorder patients at high risk for graft rejection with accept-
able rates of TRM and GVHD.
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STANDARDIZATION OF CFU ASSAYS FOR CORD BLOOD (CB) PRODUCTS
Clarke, E. for the NMDP Proﬁciency Testing Committee. StemCell
Technologies Inc., Vancouver, BC, Canada.
The advantages of using CB derived cells for the treatment of
leukemia and other hematological malignancies are now well rec-
ognized. However, the selection of the most appropriate CB prod-
uct could be enhanced if functional data, e.g., a colony forming cell
(CFC) assay was available. Such data may only be of utility if
centers elect to use a standardized protocol and agree to report on
similar criteria, so in association with the NMDP, a proﬁciency
testing program was designed speciﬁcally to evaluate the challenges
and variability of CFC assessment from both fresh and frozen CB
samples. Unprocessed fresh CB cells from a designated bank were
shipped to 28 participants who were asked to perform a total
nucleated cell count (TNC) and viability assessment and transfer a
ﬁxed number of viable cells to the tube of MethoCult™ provided.
Following 14 days, participants were asked to score and report
BFU-E, CFU-GM and total CFC numbers. All centers reported
data for all variables. In the second program, 41 participants re-
ceived a vial of frozen CB cells from a designated bank and asked
to perform similar analyses. All centers reported values for TNC
and viability but only 60% of participants reported growth of
progenitors. The coefﬁcient of variation (CV) for cell assessment
from fresh CB was signiﬁcantly lower than that from frozen CB,
though the CVs for CFCs were similar.
Investigation as to the reported lack of growth at 40% of centers
is underway. There was no statistically signiﬁcant association be-
tween shipping method (cryo-shippers or dry ice) and CFC
growth, but the reported TNC numbers correlated with CFC
proliferation, suggesting transient warming of the samples or an
extended time frame between thawing, sampling and plating.
These data suggest that adherence to standardized protocols for
cell assessment and colony enumeration may facilitate global ap-
plicability of data generated at various banks.
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TRANSPLANTATION OUTCOME OF PLASMA DEPLETED CORD BLOOD
UNIT AND THE EFFECT OF POST-THAW WASHING
Chow, Robert,1,8 Nademanee, Auayporn,2 Rosenthal, Joseph,2
Karanes, Chatchada,2 Jaing, Tang-Her,3 Graham, Michael,4
Wang, Brian,5 Gjertson, David,5 Chan, Lee Lee,6 Eames, Gretchen,7
Tan, Ah Moy,9 Tan, Poh-Lin,10 Lin, Hai-Peng,11 Tan, Patrick,12
Petz, Lawrence.1,5 1StemCyte International Cord Blood Center, Arcadia,
CA, & StemCyte Taiwan National Cord Blood Center, Linko, Taiwan;
2City of Hope National Medical Center, Duarte, CA; 3Chang Gung
University & Children’s Hospital, Linko, Taiwan; 4University of Ari-
zona Medical Center, Tuscon, CA; 5UCLA Medical Center & School of
Public Health, Los Angeles, CA; 6University of Malaya Medical Center,
Kuala Lumpar, Malaysia; 7Cook Children’s Hospital, Fort Worth, TX;
8StemCyte Research Institute, Arcadia, CA; 9KK Women & Children’s
Hospital, Singapore; 10National University Hospital, Singapore; 11Sub-
ang Jaya Medical Center, Kuala Lumpar, Malaysia; 12Mount Elizabeth
Hospital, Singapore.
We studied the outcome of cord blood transplantation (CBT)
using two approaches to maximize cord blood (CB) cell dose—
depletion of plasma (PD) but not of red blood cells during CB
processing, and no post-thaw washing (NW). All 237 known PD
CB used in 215 patients up to 3/2006 were analyzed; median age 9
yo, range 0.3-59 with 33% 16 yo; median weight 30 kg, range
4.5-112 with 35% 50 kg; male 60%; median #HLA ABDR
matches 4.0; median TNC dose 5.3  107/kg; median CD34 dose
1.8  105/kg; transplant center reported median post-thaw TNC
dose of 4.4  107/kg; malignant indications 70%; transplants
outside U.S. 39%; double transplant 27%; and non-myeloablative
16%. The incidence of grade III-IV aGVHD and extensive
cGVHD was 13% and 14% respectively. Unadjusted engraftment
rate of ANC500, platelet 20,000 and 50,000 engraftment were 88
 3%, 82  4% and 76  4% respectively. The median time to
engraftment for ANC 500, platelet 20,000 and 50,000 was 22, 48,
and 63 days respectively. Relapse rate was 23  4% and TRM was
29  3%. With a median follow-up of 325 days, 1-year overall
survival and disease-free survival are 59  4% and 54  4%
respectively. Stratiﬁcation analysis showed worse engraftment and
survival outcome at CD34 cell dose below 0.7  107/kg.
There were 113 washed (W) and 95 non-washed (NW) PD
CBTs. No signiﬁcant adverse events occurred when the recom-
mended DMSO threshold of 1g per kg recipient weight was not
exceeded. TNC recovery after thawing as reported by transplant
centers is higher for NW (median 89% vs 75%).
Table 6. Mean Cell Values Obtained by CB Centers
CVs from
Fresh CB
(n  28)
CVs from
Frozen CB
(n  41)
TNC (106/mL) 6.1% 16.5%
Viability 3.2% 35.7%
Total viable cells (106/mL) 6.4% 40.9%
BFU-E 40.6% 40.4%
CFU-GM 65.0% 55.0%
Total CFC 34.4% 35.3%
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